COVID-19 outcomes of venovenous extracorporeal membrane oxygenation for acute respiratory failure vs historical cohort of non-COVID-19 viral infections

Sagar B Dave,1 Ronald Rabinowitz,2 Aakash Shah,3 Ali Tabatabai,4 Samuel M Galvagno Jr,5 Michael A Mazzeffi,6 Raymond Rector,7 David J Kaczorowski,8 Thomas M Scalea9 and Jay Menaker10

Abstract
Introduction: Veno-venous extracorporeal membrane oxygenation (VV ECMO) has become a support modality for patients with acute respiratory failure refractory to standard therapies. VV ECMO has been increasingly used during the current COVID-19 pandemic for patients with refractory respiratory failure. The object of this study was to evaluate the outcomes of VV ECMO in patients with COVID-19 compared to patients with non-COVID-19 viral infections.

Methods: We retrospectively reviewed all patients supported with VV ECMO between 8/2014 and 8/2020 whose etiology of illness was a viral pulmonary infection. The primary outcome of this study was to evaluate in-hospital mortality. The secondary outcomes included length of ECMO course, ventilator duration, hospital length of stay, incidence of adverse events through ECMO course.

Results: Eighty-nine patients were included (35 COVID-19 vs 54 non-COVID-19). Forty (74%) of the non-COVID-19 patients had influenza virus. Prior to cannulation, COVID-19 patients had longer ventilator duration (3 vs 1 day, \( p = .003 \)), higher PaCO2 (64 vs 53 mmHg, \( p = .012 \)), and white blood cell count (14 vs 9 \( \times 10^3/\mu L \), \( p = .004 \)). Overall in-hospital mortality was 33.7% (\( n = 30 \)). COVID-19 patients had a higher mortality (49% vs. 24%, \( p = .017 \)) when compared to non-COVID-19 patients. COVID-19 survivors had longer median time on ECMO than non-COVID-19 survivors (24.4 vs 16.5 days \( p = .03 \)) but had a similar hospital length of stay (HLOS) (41 vs 48 Extracorporeal Membrane Oxygenation days \( p = .33 \)).

Conclusion: COVID-19 patients supported with VV ECMO have a higher mortality than non-COVID-19 patients. While COVID-19 survivors had significantly longer VV ECMO runs than non-COVID-19 survivors, HLOS was similar. This data add to a growing body of literature supporting the use of ECMO for potentially reversible causes of respiratory failure.
Introduction
The 1918 Spanish influenza pandemic, claimed over 50 million lives worldwide. Over the next 90 years, the treatments and approach for viral respiratory pandemics have evolved. In 2009, the publication of the CESAR trial marked a resurgence in the use of veno-venous extracorporeal membrane oxygenation (VV ECMO), a support modality historically used in the pediatric population, in adults with respiratory failure. The improvement in technology and increase in refractory respiratory failure during the 2009 Influenza H1N1 outbreak quickly brought VV ECMO to the forefront. Reports from Italy, Australia, and New Zealand showed a trend towards increased survival with VV ECMO support in patient with H1N1. In 2013, Avian influenza A (H7N9) carried a mortality greater than 60% and during this pandemic, centers in China showed VV ECMO to be a feasible and important supportive modality in refractory respiratory failure. Furthermore, in 2015, Middle East respiratory syndrome-related coronavirus (MERS-CoV) carried a mortality rate 34.4% and the use of VV ECMO showed significantly lower mortality when compared to conventional therapy.

One hundred years after the Spanish flu, the virus known as SARS-CoV-2 was discovered to cause coronavirus disease 2019 (COVID-19). By March 2020, this global pandemic extended from Asia through Europe to North America leading to a dramatic loss of human life worldwide compared to previous viral respiratory pandemics. VV ECMO has shown a promising role in the treatment plan for these patients and may play a pivotal role in this pandemic. There are many differences between COVID-19 and other viral illnesses including pathophysiology, clinical presentation, and management challenges during resource strained settings. Current literature is mixed in comparison of COVID-19 and non-COVID-19 viral illness supported with VV ECMO in regards to survival, pre-cannulation factors, and hospital course.

The purpose of this study was to evaluate outcomes in patients with COVID-19 and non-COVID-19 viral illness supported with VV ECMO at a tertiary care high volume ECMO center. We hypothesize that COVID-19 patients supported with VV ECMO will have a higher mortality than patients with non-COVID-19 viral illnesses requiring VV ECMO support.

Materials and methods
Patient selection
The institutional review board (IRB) at University of Maryland, Baltimore approved the study (HP-00093048), which waived the need for consent. All patients admitted to the Lung Rescue Unit (LRU), a dedicated intensive care unit for patients on VV ECMO, and the Biocontainment Unit (BCU), a dedicated intensive care unit for patients with COVID-19 on VV ECMO, were identified from August 2014 to August 2020 and were included in the study. The cohort of COVID-19 patients that required VV ECMO were a part of the initial surge of patients in our institution in a resource strained setting during the beginning of the COVID-19 pandemic. All patients included in this study were stratified by indications for cannulation of COVID-19 or other respiratory viral illness (non-COVID-19), then further stratified by non-survivors and survivors. Pre-ECMO and ECMO-related were collected for all patients. Sequential Organ Failure Assessment (SOFA) and Respiratory ECMO Survival Prediction (RESP) scores were calculated to assess overall organ dysfunction and pre-ECMO severity of acute respiratory distress syndrome (ARDS). The study’s primary endpoint was in-hospital mortality.

Clinical outcomes
The primary outcomes of this study was to evaluate in-hospital mortality. The secondary outcomes included pre-ECMO variables, length of ECMO course, ventilator duration, hospital length of stay, incidence of adverse events through ECMO course including pneumothorax, blood stream infections and acute renal failure requiring renal replacement therapy, and discharge data.

VV ECMO management
The decision to cannulate a patient for VV ECMO is made in a multi-disciplinary fashion by a small cohort of experienced physicians based on our institutional
The institutional preferred cannulation strategy is a peripheral, two site cannulation with a femoral vein cannula for drainage and a separate internal jugular vein cannula for return of blood. No dual lumen catheters were used during the study period. Once cannulated for VV ECMO, a lung-protective ventilator strategy is implemented. Utilizing pressure control ventilation, total pressure is set to 20 = cm H2O with a positive end-expiratory pressure of 10 cm H2O and respiratory rate of 10 = breaths per minute. Inspiratory and expiratory times are set at a 1:1 ratio. FiO2 on the ventilator is decreased as tolerated to 30% to maintain a peripheral capillary oxygen saturation (SpO2) of ≥ 88%. Gas flows to the VV ECMO circuit were fixed at a FiO2 of 100%, and the ECMO flow rates (liters per minute) were titrated to achieve a SpO2 of ≥ 88%. Sweep gas flow rates (in liters per minute) were titrated to maintain a partial pressure of carbon dioxide (PaCO2) of 35–45 mmHg based on patient’s arterial blood gas analysis. For patients with impaired right ventricular function diagnosed on formal echocardiography a lower PaCO2 goal (35–40 mm Hg) was utilized to minimize right ventricular afterload. Our institutional practice is to utilize low dose epinephrine for inotropic support and inhaled prostacyclin in cases of right ventricular dysfunction. Patients were transfused with packed red blood cells to maintain a hemoglobin goal of ≥ 7 mg/dL. Platelets were transfused for a count ≤ 40,000/μL or active bleeding.

There were two units that cared for the patients supported with VV ECMO over this study period. The LRU was a 6 bed unit that existed before the COVID-19 pandemic and cared for all non-COVID-19 VV ECMO patients. The BCU was a 16 bed unit behind a single airlock that was created in response to the COVID-19 pandemic and admitted up to 32 patients during the initial 3 months of the pandemic with double-bunking to face a large surge of critically-ill patients. Both units were staffed by a small, dedicated group of intensive care physicians and advanced practice providers.

Analysis

A descriptive analysis stratified by etiology of illness that required VV ECMO cannulation was performed. Continuous variables were reported as the median and interquartile range (IQR) and categorical variables were reported as the number and percentage of patients. Descriptive statistics were generated using mean (with standard deviation) for parametric data, median (with interquartile range) for nonparametric data, and counts with proportions for categorical data. Data were compared using chi-square or t-test for categorical and continuous variables, respectively, with 2-sided p-values < 0.05 considered statistically significant.

Results

Eighty-nine patients with median age of 47 years [IQR 38, 54] were included in this cohort (Table 1). Sixty-three (70%) patients were male and median body mass index (BMI) was 33 kg/m2 [IQR 27.5, 37.9]. Overall mortality for the entire cohort was 33.7% (n = 30).

Thirty-five (39%) patients were cannulated due to COVID-19 and fifty-four (61%) patients were cannulated due to non-COVID-19 viral respiratory infections (Table 1). Non-COVID-19 infections included influenza A and B (combined 76%), adenovirus, and metapneumovirus. COVID-19 patients were younger, had a lower incidence of coronary artery disease, hypertension, and chronic obstructive airway disease (COPD)/asthma. Prior to cannulation, COVID-19 patients had more days on the ventilator, higher white blood cell counts, higher PaCO2, a lower serum bicarbonate level, and a lower serum creatinine. Two (6%) COVID-19 patients and seven (13%) non-COVID-19 patients were on renal replacement therapy (RRT) prior to cannulation (p = .27). Eight (23%) COVID-19 patients and 24 (44%) non-COVID-19 patients went on RRT after initiation of ECMO support (p = .04).

Forty-two (47%) patients had bacteremia during their hospital stay (Table 2). COVID-19 patients had a higher incidence of bacteremia than non-COVID-19 patients [35 (71%) vs 14 (26%), p < .001]. In addition, 4 (7%) non-COVID-19 patients had fungemia during their hospital stay. More COVID-19 patients had a pneumothorax than non-COVID-19 patients [21 (60%) vs 15 (28%), p = .002]. COVID-19 patients developed pneumothoraces at a higher incidence both before and after cannulation for VV ECMO than non-COVID-19 patients (Figure 1).

COVID-19 patients had a higher mortality (49% vs. 24%, p = .017) compared to non-COVID-19 patients (Table 1). Of the entire cohort, 69% (61/89) were decannulated from VV ECMO. Non-COVID-19 patients had a higher rate of decannulation from VV ECMO [78% (42/54) vs 51% (18/35)]. Only one patient in the cohort was cannulated from VV ECMO then proceeded to die before hospital discharge. 61% (33/54) of non-COVID-19 viral patients compared to 37% (13/35) of COVID patients were liberated from ventilator support prior to hospital discharge or transfer. When further stratified by survival, COVID-19 survivors had longer median time on ECMO than non-COVID-19 survivors (585 vs 395 h p = .03) but had a similar hospital length of stay (41 vs 48 days p = .33).
### Table 1. All viral and comparison of non-COVID-19 and COVID-19 demographics, pre-extracorporeal membrane oxygenation (ECMO), ECMO variables, and outcomes.

| Patient characteristic | Median [IQR] or n (%) | p-value |
|------------------------|-----------------------|---------|
|                        | All (n = 89)          | Non-COVID-19 (n = 54) | COVID-19 (n = 35) |
| Age                    | 47 [38, 54]           | 50 [41.25, 56]         | 43 [37, 50]        | .03 |
| Sex - M                | 63 (71%)              | 33 (61%)              | 30 (86%)           | .13 |
| BMI (kg/m^2)           | 33 [27.5, 37.9]       | 33.2 [28.0, 37.2]      | 32.4 [26.9, 39.2]  | .59 |
| Coronary artery disease| 5 (5.6%)              | 5 (9.3%)              | 0 (0%)             | .024 |
| Diabetes mellitus      | 20 (22.5%)            | 9 (16.7%)             | 11 (31.4%)         | .10 |
| Liver disease          | 2 (2.2%)              | 2 (3.7%)              | 0 (0%)             | .16 |
| Congestive heart failure| 3 (3.4%)             | 3 (5.6%)              | 0 (0%)             | .083 |
| COPD/Asthma            | 19 (21.3%)            | 17 (31.5%)            | 2 (5.7%)           | .004 |
| Substance abuse        | 9 (10%)               | 8 (14.8%)             | 1 (4.6%)           | .68 |
| Hypertension           | 43 (48.3%)            | 31 (57.4%)            | 12 (34.3%)         | .03 |
| Ventilation days before ECMO | 2 [1, 4]  | 1 [0.25, 3]          | 3 [1.5, 4.5]       | .003 |
| Creatinine (mg/dl) before ECMO | 1.25 [0.79, 2.95] | 1.7 [1.1, 3.5]         | 0.85 [0.67, 1.5] < .001 |
| Lactate before ECMO    | 2.2 [1.5, 3.4]        | 2.1 [1.4, 4.2]        | 2.2 [1.9, 2.9]     | .45 |
| WBC before ECMO        | 11.8 [7, 17]          | 8.8 [4.6, 14.8]       | 14.1 [9.7, 20.5]   | .004 |
| Bicarb before ECMO     | 72.4 [7.16, 7.32]     | 7.23 [7.15, 7.32]     | 7.28 [7.19, 7.32]  | .25 |
| pH                     | 72.4 [7.16, 7.32]     | 7.23 [7.15, 7.32]     | 7.28 [7.19, 7.32]  | .25 |
| P/F ratio              | 69 [56, 84]           | 67 [56, 84]           | 73 [57, 79]        | .70 |
| PaCO2 (mmHg)           | 55 [45, 66]           | 53 [43, 63]           | 64 [51, 78]        | .01 |
| PIP (cm H2O)           | 37 [33, 41]           | 36 [33, 40]           | 37 [33, 41]        | .52 |
| PEEP (cm H2O)          | 16 [14, 18]           | 16 [14, 18]           | 16 [14, 18]        | .94 |
| RESP Score             | 3 [2, 5]              | 3 [2, 5]              | 3 [2, 5]           | 0.53 |
| SOFA Score             | 3 [2, 5]              | 3 [2, 5]              | 3 [2, 5]           | .53 |
| ECMO duration (hours)  | 11 [9, 13]            | 11 [9.5, 14]          | 12 [7, 12]         | .02 |
| Hospital LOS (days)    | 45 [24, 58]           | 41 [22, 57]           | 48 [30, 59]        | .33 |
| CRRT                   | 41 (46.1%)            | 31 (57%)              | 10 (29%)           | < .001 |
| MARS                   | 1 (1.1%)              | 1 (2%)                | 0 (0%)             | .32 |
| Prone positioning      | 67 (75.3%)            | 39 (72%)              | 28 (80%)           | .41 |
| Steroids               | 62 (69.7%)            | 33 (61%)              | 29 (83%)           | .03 |
| In-hospital mortality  | 30 (33.7%)            | 13 (24%)              | 17 (49%)           | .02 |

ECMO: Extracorporeal Membrane Oxygenation; n: number; IQR: Interquartile Range; M: Male; BMI: Body Mass Index; Cr: Creatinine; WBC: white blood cell count; P/F: ratio of arterial oxygen partial pressure to fractional inspired oxygen; PaCO2: Partial Pressure of Carbon Dioxide; PIP: Peak Inspiratory Pressure; PEEP: Positive End Expiratory Pressure; RESP: Respiratory ECMO Survival Prediction; SOFA: Sequential Organ Failure Assessment; LOS: Length of Stay; CRRT: Continuous Renal Replacement Therapy; MARS: Molecular Adsorbent Recirculating System.

### Table 2. Number of Patients with Adverse events through extracorporeal membrane oxygenation Course.

| Adverse events      | Median [IQR] or n (%) | p-value |
|---------------------|-----------------------|---------|
|                     | All (n = 89)          | Non-COVID-19 (n = 54) | COVID-19 (n = 35) |
| Bacteremia          | 39 (44%)              | 25 (71%)          | 14 (26%)          | < .001 |
| Fungiemia           | 4 (4%)                | 0 (0%)            | 4 (7%)            | .15 |
| Pneumothorax        | 36 (40%)              | 15 (28%)          | 21 (60%)          | .002 |
| Oxygenator changes  | 41 (46%)              | 20 (57%)          | 21 (39%)          | .09 |

n: number; IQR: Interquartile Range
Figure 1. Incidence of pneumothorax. Legend: ECMO: Extracorporeal Membrane Oxygenation. Incidence of pneumothorax before ECMO: Non-COVID-19 (1) vs COVID-19 (7), \( p = .003 \). Incidence of pneumothorax after ECMO: Non-COVID-19 (14) vs COVID-19 (18), \( p = .01 \)
Discussion

The use of VV ECMO in the adult population has increased since the publications of the CESAR trial and many reports of the role extracorporeal life support played during the 2009 H1N1 influenza pandemic. Our institution has previously demonstrated a 15.4% mortality rate for patients supported with VV ECMO for severe influenza-related ARDS. This is significantly lower when compared to those not supported with VV ECMO. Despite success in previous respiratory pandemics, there is limited data comparing the role of VV ECMO in COVID-19 to other viral illnesses. In this study, we have demonstrated that COVID-19 patients supported with VV ECMO have a survival of 51%, which is comparable to the 49% survival reported in the Extracorporeal Life Support Organization registry. We further explored the differences between COVID-19 and non-COVID-19 patients supported with VV ECMO. Our study showed that COVID-19 patients had a higher mortality than non-COVID-19 patients despite being younger, having a lower chronic disease burden and less organ failure at time of cannulation.

Survival for adult patients with severe respiratory failure secondary to viral pneumonia requiring ECMO is reported to be approximately 63%. At our institution, a higher survival rate was observed for non-COVID-19 patients. Patient selection, regional disease patterns, selection criteria, and our dedicated unit to providing VV ECMO at a high volume center are all variables that may explain this lower mortality rate. However, our study also reported a lower survival rate in COVID-19 than non-COVID-19 viral illnesses, which is an inconsistent finding with current worldwide experience.

Difference in mortality may be due to significantly longer time on the ventilator prior to VV ECMO cannulation in COVID-19. This is in contrast to other studies which showed longer time on the ventilator with COVID-19 patients compared to survivors to non-COVID-19 patients. Time on the ventilator prior to cannulation has been shown to be inversely related to survival. Our approach is in line with ELSO guidelines, which recommend greater than 7 days of ventilator time as a relative contraindication for cannulation for VV ECMO. This inverse relationship between survival and ventilator time prior to cannulation has been attributed to ventilator induced lung injury (VILI) in traditional ARDS. With COVID-19, this may be more pronounced due to the proposed thromboinflammatory response in the pulmonary structures. Our study data showed non-COVID-19 patients had less time on the ventilator prior to ECMO cannulation and had a higher survival rate. This suggests that less time on the ventilator prior to ECMO support may improve outcomes when comparing non-COVID-19 and COVID-19 patients. Future studies need a focused evaluation on the association with earlier cannulation and survival.

Pneumothorax has been an identified complication with mechanical ventilation and ARDS. It portends a poor prognosis and may have played a role in the difference in mortality between the two groups in our study. COVID-19 patients may have a higher risk of pneumothorax due to inherent difference in disease process. In our study, more COVID-19 patients had pneumothoraces than non-COVID-19 patients. Patients with COVID-19 also had increase rates of pneumothorax prior to cannulation as well as post-cannulation. Compared to previously reported experiences, our COVID-19 cohort had a higher rate of pneumothorax. VILI and patient self-induced lung injury seen in COVID-19 patients due to extended time on the ventilator prior to cannulation may have led to this difference. This data further suggests reducing time on the ventilator prior to cannulation, as ECMO has been shown to decrease the rate of pneumothorax particular in high risk patients with ARDS.

In our study, non-COVID-19 patients had a higher incidence of acute kidney injury and use of RRT both before and after cannulation for VV ECMO, which is similar to current literature. As our institution limited VV ECMO support in COVID-19 patients with severe renal impairment or those already on renal replacement therapy, this may account for the difference in groups prior to cannulation. Limited literature on acute kidney injury and RRT for COVID-19 patients shows a trend towards poor outcomes. Although there is a high rate of renal recovery for VV ECMO survivors, there is a well-established increase in mortality for VV ECMO patients who require simultaneous renal replacement. Despite the high incidence of kidney injury and use of RRT in the non-COVID-19 population, mortality was still higher in the COVID-19 cohort.

Time on ECMO was longer for the COVID-19 group compared to the non-COVID-19 group, as well what is reported in other series of COVID-19 patients supported with VV ECMO. One factor that may explain our longer ECMO times in COVID-19 survivors compared to non-COVID-19 survivors was the decision to extend no-sweep trials prior to decannulating COVID 19 patients. The non-COVID-19 patients had a 24 h no-sweep trial as a standard practice. However, COVID-19 patients had a 72 h no-sweep trial prior to decannulation due to concerns for emergent recannulation in an...
airlock unit. As our approach was to decannulate prior to extubation, we had a shorter time on ECMO for COVID-19 compared to others that utilized a dual-lumen cannulation approach with an early extubation strategy. The optimal strategy for early or delayed extubation or decannulation remains to be determined for patients with COVID-19 supported on VV ECMO.

The difference in mortality and patient demographics may have been due to the difference in the specific units and systematic criteria. The LRU had a small group of attending physicians and providers that specialized in the care of patients with VV ECMO. Each patient was in their own room with specific precautions and a dedicated nurse. The BCU was a single unit behind a single airlock that admitted up to 32 patients with double-bunking to face a large surge of critically-ill patients. Furthermore, due to resource allocation during the pandemic, providers, including physicians, advanced practitioners, nurses, respiratory therapists, ECMO specialists, were from varied backgrounds.

As an institution, VV ECMO selection criteria was stricter due to the reports of severity of ARDS associated with COVID-19. In preparation for a surge of refractory respiratory failure with COVID-19 and suspected poor outcomes with traditional criteria, selection criteria was adjusted. Notable differences from previous non-COVID-19 VV ECMO criteria were age and BMI. Age has been previously noted to be an independent predictor of outcomes in VV ECMO. The age cutoff was adjusted to 55 years due to the high mortality rate above this age group seen in other experiences with COVID-19. Obesity itself has various reports on outcomes with patients supported on VV ECMO. Obesity has been cited as a risk factor for poor outcomes in critically ill patients and has raised technical concerns for vascular access from various institutions. Yet Galvagno, et al., Kon, et al. and the PRESERVE study suggest that obesity itself should not routinely be considered a contraindication to VV ECMO support and may have a protective paradoxical improvement in outcomes. However, the mortality associated with obesity in COVID-19 patients led us to use a BMI > 40 kg/m2 as a relative contraindication. As a result of these changes in the institution’s inclusion and exclusion criteria, there were differences between COVID-19 and non-COVID-19 patient’s age, BMI, and comorbidities. Yet despite these differences, specifically in age which is universally accepted to be associated with outcomes, COVID-19 patients had higher rates of mortality. Though mortality for COVID-19 patients has improved over time, experience from post-pandemic influenza H1N1, shows populations are vulnerable and still at risk after the initial surge and ECMO implementation may continue to be needed in the future.

**Limitations**

This study has several limitations. This was a single center study based on a retrospective chart review which may have missed key variables. Difference between the physical units, staffing models, and larger pool of providers working with COVID-19 patients may have been factors that were not individually analyzed. As different therapies emerge for COVID-19, it is possible that mortality may decrease, possibly approaching rates closer to those observed historically for severe viral pneumonias requiring VV ECMO. Furthermore, changes in patient selection criteria may have contributed to differences that were not examined.

**Conclusion**

In this single center study, COVID-19 patients supported with VV ECMO had a higher mortality when compared to patients with other viral illness. Although COVID-19 survivors had a significantly longer time on VV ECMO compared to non-COVID-19 survivors, both had similar HLOS. Future efforts to reduce mortality should focus on appropriate patient selection and optimization of care once on VV ECMO.

**Declaration of conflicting interests**

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Funding**

The author(s) received no financial support for the research, authorship, and/or publication of this article.

**ORCID iDs**

Sagar B Dave
[https://orcid.org/0000-0001-8859-6491](https://orcid.org/0000-0001-8859-6491)

Aakash Shah
[https://orcid.org/0000-0003-2302-733X](https://orcid.org/0000-0003-2302-733X)

Ali Tabatabai
[https://orcid.org/0000-0002-5325-4907](https://orcid.org/0000-0002-5325-4907)

Samuel M Galvagno
[https://orcid.org/0000-0001-5563-4092](https://orcid.org/0000-0001-5563-4092)

Michael A Mazzefi
[https://orcid.org/0000-0003-2955-4915](https://orcid.org/0000-0003-2955-4915)

**References**

1. Taubenberger JK and Morens DM. Influenza: the mother of all pandemics. Emerg Infect Dis 2006 12: 15–22.
2. Peek GJ, Clemens F, Elbourne D, et al. CESAR: conventional ventilatory support vs extracorporeal...
membrane oxygenation for severe adult respiratory failure. *BMC Health Serv Res* 2006; 6: 163.

3. Patroniti N, Zangrillo A, Pappalardo F, et al. The Italian ECMO network experience during the 2009 influenza A(H1N1) pandemic: preparation for severe respiratory emergency outbreaks. *Intensive Care Med* 2011; 37: 1447–1457.

4. Australia. New Zealand Extracorporeal Membrane Oxygenation Influenza Investigators, Davies A, Jones D, et al. Extracorporeal membrane oxygenation for 2009 influenza A(H1N1) acute respiratory distress syndrome. *JAMA* 2009; 302: 1888–1895.

5. Huang L, Zhang W, Yang Y, et al. Application of extracorporeal membrane oxygenation in patients with severe acute respiratory distress syndrome induced by avian influenza A (H7N9) viral pneumonia: national data from the Chinese multicentre collaboration. *BMC Infect Dis* 2018; 18: 23.

6. Sohrabi C, Alsafi Z, O’Neill N, et al. World health organization declares global emergency: a review of the 2019 novel coronavirus (COVID-19). *Int J Surg* 2020; 76: 71–76.

7. Alshahrani MS, Sindhi A, Alshamsi F, et al. Extracorporeal membrane oxygenation for severe Middle East respiratory syndrome coronavirus. *Ann Intensive Care* 2018; 8: 3.

8. Ashton J. COVID-19 and the ‘Spanish’ flu. *J R Soc Med* 2020; 113: 197–198.

9. Omer SB and Malani P and Del Rio C. The COVID-19 pandemic in the US: a clinical update. *JAMA* 2020; 323: 1767–1768.

10. Li X, Guo Z, Li B, et al. Extracorporeal membrane oxygenation for coronavirus disease 2019 in Shanghai, China. *ASAIO J* 2020; 66: 475–481.

11. Bartlett RH, Ogino MT, Brodie D, et al. Initial ELSO guidance document: ECMO for COVID-19 patients with severe cardiopulmonary failure. *ASAIO J* 2020; 66: 472–474.

12. Raff LA, Reid TD, Johnson D, et al. Comparative outcomes between COVID-19 and influenza patients placed on veno-venous extracorporeal membrane oxygenation for severe ARDS. *Am J Surg* 2021; 223(2):388–394.

13. Garfield B, Bianchi P, Arachchilage D, et al. Six month mortality in patients with COVID-19 and non-COVID-19 viral pneumonia managed with veno-venous extracorporeal membrane oxygenation. *ASAIO J* 2021; 67: 982–988.

14. Chong WH and Saha BK and Medarov BI. Clinical characteristics between survivors and nonsurvivors of COVID-19 patients requiring extracorporeal membrane oxygenation (ECMO) support: a systematic review and meta-analysis. *J Intensive Care Med* 2021; 37: 8850666210145632.

15. Shah A, Dave S, Galvagno S, et al. A dedicated veno-venous extracorporeal membrane oxygenation unit during a respiratory pandemic: lessons learned from COVID-19 Part II: clinical management. *Membranes (Basel)* 2021: 11: 306.

16. Haider B, Khan MI, Burke WM, et al. Ischemic heart failure: sustained inotropic response to small doses of l-epinephrine without toxicity. *Am J Cardiol* 1975; 35: 504–513.

17. Buchner J, Mazzetti M, Kon Z, et al. Single-center experience with venovenous ECMO for influenza-related ARDS. *J Cardiotoracic Vase Anesth* 2018; 32: 1154–1159.

18. Extracorporeal Life Support Organization (ELSO). Registry dashboard of ECMO-supported COVID-19 patient data, 2021, www.elso.org/registry/FullCOVID-19RegistryDashboard.aspx (accessed on 10 March 2021).

19. Prawiratut K, Hirsch RL, Steimle CN, et al. Mortality is directly related to the duration of mechanical ventilation before the initiation of extracorporeal life support for severe respiratory failure. *Crit Care Med* 1997; 25: 28–32.

20. Masiaots PT, Islam S, Doody DP, et al. Extracorporeal membrane oxygenation for nonneonatal acute respiratory failure. *Arch Surg* 1999; 134: 375–379, discussion 379-380.

21. Shekar K, Badulak J, Peak G, et al. Extracorporeal life support organization coronavirus disease 2019 interim guidelines: a consensus document from an international group of interdisciplinary extracorporeal membrane oxygenation providers. *ASAIO J* 2020; 66: 707–721.

22. Ciceri F, Beretta L, Scandroglio AM, et al. Microvascular COVID-19 lung vessels obstructive thromboinflammatory syndrome (MicroCLOTS): an atypical acute respiratory distress syndrome working hypothesis. *Crit Care Resusc* 2020; 22: 95–97.

23. Gattinoni L, Bombino M, Pelosi P, et al. Lung structure and function in different stages of severe adult respiratory distress syndrome. *JAMA* 1994; 271: 1772–1779.

24. Janssen ML, Van Manen MJG, Cretier SE, et al. Pneumothorax in patients with prior or current COVID-19 pneumonia. *Respir Med Case Rep* 2020; 31: 101187.

25. Yang F, Shi S, Zhu J, et al. Analysis of 92 deceased patients with COVID-19. *J Med Virol* 2020; 92: 2511–2515.

26. Salehi S, Abedi A, Balakrishnan S, et al. Coronavirus disease 2019 (COVID-19): a systematic review of imaging findings in 919 patients. *AJR Am J Roentgenol* 2020; 215: 87–93.

27. López Vega JM, Parra Gordo ML, Diez Tascon A, et al. Pneumomediastinum and spontaneous pneumothorax as an extrapulmonary complication of COVID-19 disease. *Emerg Radiol* 2020; 27: 727–730.

28. Schmidt M, Hajjage D, Lebreton G, et al. Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome associated with COVID-19: a retrospective cohort study. *Lancet Respir Med* 2020; 8: 1121–1131.

29. Otani T, Ohshimo S, Ota K, et al. Prevention of pneumothorax using venovenous ECMO in acute respiratory distress syndrome with emphysematous/cystic changes in the lung. *Crit Care* 2014; 18(Suppl 1): P334.

30. Barbaro RP, MacLaren G, Boonstra PS, et al. Extracorporeal membrane oxygenation support in COVID-19: an international cohort study of the Extracorporeal Life Support Organization registry. *Lancet* 2020; 396: 1071–1078.
31. Wilbers TJ and Koning MV. Renal replacement therapy in critically ill patients with COVID-19: a retrospective study investigating mortality, renal recovery and filter lifetime. J Crit Care 2020; 60: 103–105.
32. Chen H, Yu RG, Yin NN, et al. Combination of extracorporeal membrane oxygenation and continuous renal replacement therapy in critically ill patients: a systematic review. Crit Care 2014; 18: 675.
33. Deatrick KB, Mazzefi MA, Galvagno SM Jr., et al. Breathing life back into the kidney-continuous renal replacement therapy and veno-venous extracorporeal membrane oxygenation. ASAIO J 2021; 67: 208–212.
34. Yang Y, Rali AS, Inchaustegui C, et al. Extracorporeal membrane oxygenation in coronavirus disease 2019-associated acute respiratory distress syndrome: an initial US experience at a high-volume centre. Card Fail Rev 2020; 6: e17.
35. Kon ZN, Smith DE, Chang SH, et al. Extracorporeal membrane oxygenation support in severe COVID-19. Ann Thorac Surg 2021; 111: 537–543.
36. Mustafa AK, Alexander PJ, Joshi DJ, et al. Extracorporeal membrane oxygenation for patients with COVID-19 in severe respiratory failure. JAMA Surg 2020; 155: 990–992.
37. Henry BM and Lippi G. Poor survival with extracorporeal membrane oxygenation in acute respiratory distress syndrome (ARDS) due to coronavirus disease 2019 (COVID-19): Pooled analysis of early reports. J Crit Care 2020; 58: 27–28.
38. Deatrick KB, Mazzefi MA, Galvagno SM Jr., et al. Outcomes of venovenous extracorporeal membrane oxygenation when stratified by age: how old is too old? ASAIO J 2020; 66: 946–951.
39. Team CC-R, Boundy E, Bowen V, et al. Severe outcomes among patients with coronavirus disease 2019 (COVID-19) - United States, February 12–March 16, 2020. MMWR Morb Mortal Wkly Rep 2020; 69: 343–346.
40. Onder G and Rezza G and Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA 2020; 323: 1775–1776.
41. Al-Soufi S, Buscher H, Nguyen ND, et al. Lack of association between body weight and mortality in patients on veno-venous extracorporeal membrane oxygenation. Intensive Care Med 2013; 39: 1995–2002.
42. Bercault N, Boulain T, Kuteifan K, et al. Obesity-related excess mortality rate in an adult intensive care unit: A risk-adjusted matched cohort study. Crit Care Med 2004; 32: 998–1003.
43. Kon ZN, Dahi S, Evans CF, et al. Class III obesity is not a contraindication to venovenous extracorporeal membrane oxygenation support. Ann Thorac Surg 2015; 100: 1855–1860.
44. Galvagno SM Jr., Pelekhaty S, Cornachione CR, et al. Does weight matter? outcomes in adult patients on venovenous extracorporeal membrane oxygenation when stratified by obesity class. Anesth Analg 2020; 131: 754–761.
45. Schmidt M, Zogheib E, Roze H, et al. The PRESERVE mortality risk score and analysis of long-term outcomes after extracorporeal membrane oxygenation for severe acute respiratory distress syndrome. Intensive Care Med 2013; 39: 1704–1713.
46. Caussy C, Wallet F, Laville M, et al. Obesity is associated with severe forms of COVID-19. Obesity (Silver Spring) 2020; 28: 1175.
47. Esper SA, Levy JH, Waters JH, et al. Extracorporeal membrane oxygenation in the adult: a review of anticoagulation monitoring and transfusion. Anesth Analg 2014; 118: 731–743.